Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1β and prostaglandin E2 synthesis by silymarin

Biochemical Pharmacology

Volumn 67, Issue 1, 2004, Pages 175-181

  Kang, Jong Soon ^a   Jeon, Young Jin ^b   Park, Song Kyu ^a   Yang, Kyu Hwan ^a,c   Kim, Hwan Mook ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chosun University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Cyclooxygenase 2; Interleukin 1 ; NF B Rel; Prostaglandin E2; Sepsis; Silymarin

Indexed keywords

CYCLOOXYGENASE 2; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; SILYMARIN; TRANSCRIPTION FACTOR REL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; INHIBITION KINETICS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SEPSIS; SURVIVAL RATE;

EID: 0344687228     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.032     Document Type: Article

References (35)

1. Valenzuela A., Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol. Res. 27(2):1994;105-112.
2. Carini R., Comoglio A., Albano E., Poli G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem. Pharmacol. 43(10):1992;2111- 2115.
3. Mereish K.A., Bunner D.L., Ragland D.R., Creasia D.A. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharm. Res. 8(2):1991;273-277.
4. Zi X., Feyes D.K., Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 4(4):1998;1055-1064.
5. Bhatia N., Zhao J., Wolf D.M., Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett. 147(1/2):1999;77-84.
6. Valenzuela A., Guerra R., Videla L.A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med. 52(6):1986;438-440.
7. Manna S.K., Mukhopadhyay A., Van N.T., Aggarwal B.B. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 163(12):1999;6800-6809.
8. Zi X., Mukhtar H., Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem. Biophys. Res. Commun. 239(1):1997;334-339.
9. Agarwal R., Katiyar S.K., Lundgren D.W., Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13- acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis. 15(6):1994;1099-1103.
10. Bone R.C. Gram-positive organisms and sepsis. Arch. Intern. Med. 154(1):1994;26-34.
11. Rackow E.C., Astiz M.E. Pathophysiology and treatment of septic shock. J. Am. Med. Assoc. 266(4):1991;548-554.
12. Titheradge M.A. Nitric oxide in septic shock. Biochim. Biophys. Acta. 1411(2/3):1999;437-455.
13. Ando H., Takamura T., Ota T., Nagai Y., Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 294(3):2000;1043-1046.
14. Shirakawa F., Saito K., Bonagura C.A., Galson D.L., Fenton M.J., Webb A.C., Auron P.E. The human prointerleukin 1 beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol. Cell. Biol. 13(3):1993;1332-1344.
15. Dinarello C.A. Proinflammatory cytokines. Chest. 118(2):2000;503-508.
16. Fletcher J.R., Collins J.N., Graves E.D. III, Luterman A., Williams M.D., Izenberg S.D., Rodning C.B. Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition. Ann. Surg. 217(6):1993;668-674. [discussion 674-5].
17. Laneuville O., Breuer D.K., Dewitt D.L., Hla T., Funk C.D., Smith W.L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271(2):1994;927-934.
18. Lee M., Kim H.M., Yang K.H. Down-regulation of protein kinase C in murine splenocytes: a potential mechanism for 2-acetylaminofluorene-mediated immunosuppression. Cancer Lett. 101(1):1996;53-57.
19. Zhao J., Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 20(11):1999;2101-2108.
20. Jeon Y.J., Kim Y.K., Lee M., Park S.M., Han S.B., Kim H.M. Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages. J. Pharmacol. Exp. Ther. 294(2):2000;548-554.
21. Chomczynski P., Mackey K. Substitution of chloroform by bromo-chloropropane in the single-step method of RNA isolation. Anal. Biochem. 225(1):1995;163-164.
22. Pierce J.W., Lenardo M., Baltimore D. Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc. Natl. Acad. Sci. U.S.A. 85(5):1988;1482-1486.
23. Hiscott J., Marois J., Garoufalis J., D'Addario M., Roulston A., Kwan I., Pepin N., Lacoste J., Nguyen H., Bensi G., Fenton M. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13(10):1993;6231-6240.
24. Hwang D., Jang B.C., Yu G., Boudreau M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. Biochem. Pharmacol. 54(1):1997;87-96.
25. Saliou C., Rihn B., Cillard J., Okamoto T., Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett. 440(1/2):1998;8-12.
26. Dinarello C.A. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112(Suppl. 6):1997;321S-329S.
27. Rees D.D., Cellek S., Palmer R.M., Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem. Biophys. Res. Commun. 173(2):1990;541-547.
28. Natanson C., Eichenholz P.W., Danner R.L., Eichacker P.Q., Hoffman W.D., Kuo G.C., Banks S.M., MacVittie T.J., Parrillo J.E. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169(3):1989;823-832.
29. Fisher C.J. Jr., Slotman G.J., Opal S.M., Pribble J.P., Bone R.C., Emmanuel G., Ng D., Bloedow D.C., Catalano M.A. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit. Care Med. 22(1):1994;12-21.
30. Schweizer A., Feige U., Fontana A., Muller K., Dinarello C.A. Interleukin-1 enhances pain reflexes. Mediation through increased prostaglandin E2 levels. Agents Actions. 25(3/4):1988;246-251.
31. Miller-Graziano C.L., Fink M., Wu J.Y., Szabo G., Kodys K. Mechanisms of altered monocyte prostaglandin E2 production in severely injured patients. Arch. Surg. 123(3):1988;293-299.
32. Fukushima R., Alexander J.W., Wu J.Z., Mao J.X., Szczur K., Stephens A.M., Ogle J.D., Ogle C.K. Time course of production of cytokines and prostaglandin E2 by macrophages isolated after thermal injury and bacterial translocation. Circ. Shock. 42(3):1994;154-162.
33. Santangelo S., Shoup M., Gamelli R.L., Shankar R. Prostaglandin E2 receptor antagonist (SC-19220) treatment restores the balance to bone marrow myelopoiesis after burn sepsis. J. Trauma. 48(5):2000;826-830. [discussion 830-1].
34. Christman J.W., Lancaster L.H., Blackwell T.S. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 24(11):1998;1131-1138.
35. Bohrer H., Nawroth P.P. Nuclear factor kappaB - a new therapeutic approach? Intensive Care Med. 24(11):1998;1129-1130.